Abou-Alfa GK et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(6):796-807. Abstract
Abou-Alfa GK et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol 2020;21(5):671-84. Abstract
Bekaii-Saab TS et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. Gastrointestinal Cancers Symposium 2022; Abstract 519.
Goyal L et al. Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N Engl J Med 2021;384(11):1054-64. Abstract
Goyal L et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. ASCO 2022; Abstract 4009.
Javle M et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22(9):1290-300. Abstract
Lamarca A et al. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol 2020;73(1):170-85. Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022; Abstract 4006.
Subbiah V et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234-43. Abstract
Upreti D, Adeji AA. KRAS: From undruggable to a druggable cancer target. Cancer Treat Rev 2020;89:102070. Abstract
Valle JW et al. Biliary tract cancer. Lancet 2021;397(10272):428-44. Abstract
Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021 ;7(11):1669-77. Abstract